News

News and Press Releases
Research | Drug Pipeline FDA Approves Ivacaftor for Five Splice Mutations

The U.S. Food and Drug Administration (FDA) approved the use of ivacaftor (Kalydeco®) today for people ages 2 and older with cystic fibrosis who have at least one of the following five splice mutations: 3849+10kbC->T, 2789+5G->A, 3272-26A->G, 711+3A->G, E831X.

| 2 min read
Research | CFTR Modulators | Drug Pipeline FDA Approves Ivacaftor for 23 Additional CFTR Mutations

The U.S. Food and Drug Administration (FDA) today approved ivacaftor (Kalydeco®) for people ages 2 and older who have at least one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

| 3 min read
Research | Drug Pipeline Anti-Inflammatory Drug Shows Promising Early Results for CF

Corbus Pharmaceuticals reported promising results Thursday from an early stage clinical study of a potential anti-inflammatory drug for people with cystic fibrosis.

| 2 min read